UK government accepts AI health regulation reforms to boost tech sector

The UK government has accepted all 44 recommendations from the National Commission into the Regulation of AI in Healthcare, signalling a significant shift in how artificial intelligence powered medical devices are approved and monitored. This decision, announced on Tuesday, is expected to provide British technology firms with a competitive advantage by allowing them to demonstrate their innovations within the National Health Service earlier than their international counterparts. Industry experts believe this regulatory overhaul will position the United Kingdom as a leading testbed for medical innovation, potentially attracting greater investment and accelerating the commercialisation of health tech products.

Martin Turner, director of policy and external affairs at the Bioindustry Association, stated that the Medicines and Healthcare products Regulatory Agency approach makes the UK a leading environment for innovation. He explained that adopting pro-innovation strategies allows domestic innovators to test and develop products in collaboration with regulators. This process enables companies to gain proof of concept within a large healthcare system, often before their peers in other markets. Steve Lee, executive director of regulation at the Association of British Healthtech Industries, described the plans as a positive direction for the sector. He noted that a proportionate, lifecycle-based approach could help safe and innovative technologies reach patients sooner while providing clearer regulatory guidance for companies developing and investing in AI.

The proposed regulatory framework moves away from relying heavily on a single pre-market assessment. Instead, it emphasises monitoring the performance of AI medical devices throughout their entire working life. This shift aims to lower barriers for health tech companies entering the market and make Britain more attractive to investors. However, industry leaders caution that the benefits of this approach depend on the NHS actually purchasing the technology. Lee warned that continuous oversight should not translate into a continuous regulatory burden. He emphasised that regulation is only part of the solution, as companies still require a viable route into NHS adoption and procurement for innovation to translate into commercial growth. Turner similarly noted that lower barriers to entry rely on promised improvements to adoption and the NHS’s willingness to reimburse companies.

Survey data from the Commission indicates that around two-thirds of respondents believe the existing regulatory framework restricts innovation. Furthermore, 77 per cent of healthcare professionals who responded called for significant reform or a complete overhaul of the current system. In parallel with the acceptance of the commission’s recommendations, the MHRA opened applications for the third phase of its AI airlock. This regulatory sandbox allows companies to test AI medical devices alongside regulators. The latest phase will focus on monitoring technology after deployment, with the first firms due to be selected next month. Draft guidance on handling AI medical devices that change and improve over time is expected by December, with consultations on product classification planned for next year.

Turner suggested that this approach should enable companies to demonstrate proof of concept and value more quickly, potentially encouraging further investment and acquisitions. He highlighted the UK’s strengths in both life sciences and AI, noting significant interest in the ecosystem of startups and scaleups. However, he stressed the need for the government and the MHRA to ensure the UK regime remains consistent with major overseas markets. This consistency is crucial to prevent firms gaining an early advantage at home from facing new barriers when expanding abroad. Health innovation minister James Frith stated that the government wants patients to benefit from AI more quickly, while emphasising that innovation must never come at the expense of patient safety.